Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FGF401 ± PDR001 in FGFR4/KLB-positive hepatocellular carcinoma and solid tumors
CTR20160797Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of roblitinib, spartalizumab in hepatocellular carcinoma (HCC), Nonhematologic neoplasms, sponsored by Novartis. Started Feb 2017; status: completed.
02
Drugs
roblitinibspartalizumab
03
Conditions
hepatocellular carcinoma (HCC)Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20160797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160797.